Clinical and Pathologic Features Associated With Invasive Breast Carcinoma With 2018 American Society of Clinical Oncology/College of American Pathologists In Situ Hybridization Group 2 Results (Human Epidermal Growth Factor Receptor 2 [HER2]/Chromosome 17 Centromere [CEP17] Ratio ≥2.0 and Average HER2 Copy Number <4.0)
The American Society of Clinical Oncology/College of American Pathologists updated the human epidermal growth factor receptor 2 (HER2) breast carcinoma testing guideline in 2018 to address issues from uncommon HER2 fluorescence in situ hybridization (FISH) results. Based on the 2013 American Society...
Gespeichert in:
| Veröffentlicht in: | Archives of pathology & laboratory medicine (1976) 2022-06, Vol.146 (6), p.701-709 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 709 |
|---|---|
| container_issue | 6 |
| container_start_page | 701 |
| container_title | Archives of pathology & laboratory medicine (1976) |
| container_volume | 146 |
| creator | Hoda, Raza S Zarei, Shabnam McIntire, Patrick J Sprague, Cathy Mekhail, Yasmin Carlson, Diane L Komforti, Miglena K Downs-Kelly, Erinn P |
| description | The American Society of Clinical Oncology/College of American Pathologists updated the human epidermal growth factor receptor 2 (HER2) breast carcinoma testing guideline in 2018 to address issues from uncommon HER2 fluorescence in situ hybridization (FISH) results. Based on the 2013 American Society of Clinical Oncology/College of American Pathologists guideline, cases wherein the HER2/chromosome 17 centromere (CEP17) ratio of 2.0 or more with an average HER2 copy number of less than 4.0 were considered in situ hybridization (ISH) positive. Under the 2018 guideline, such cases are classified as ISH Group 2 and are no longer considered eligible for anti-HER2 therapy when the corresponding HER2 immunohistochemistry result is 0, 1+, or 2+.
To assess the clinical, pathologic, and treatment aspects of patients with ISH Group 2 results.
We retrospectively reviewed HER2 FISH results at our center between January 2012 and December 2014 and identified and characterized cases with ISH Group 2 results.
Thirty-nine cases with ISH Group 2 results from 39 patients were reviewed. Twenty of 39 (51%) patients received anti-HER2 therapy. Patients treated with HER2-targeted therapy were less likely to have hormone receptor-positive tumors, compared with patients without anti-HER2 treatment, though not significantly (P = .30). The only significant difference between the 2 patient groups was receipt of cytotoxic chemotherapy treatment (P < .001). Overall, clinical outcome was similar between the 2 groups (P > .99).
This retrospective study with median follow-up of at least 6 years shows patients with ISH Group 2 tumors had similar clinical outcomes, irrespective of HER2-targeted therapy. Further analysis in the prospective setting would provide valuable data that would potentially inform clinical decision making. |
| doi_str_mv | 10.5858/arpa.2021-0155-OA |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2576652332</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A705931985</galeid><sourcerecordid>A705931985</sourcerecordid><originalsourceid>FETCH-LOGICAL-c508t-4d60de6a0378e2383eabb566d09738201336ef0ccda941383d82237eb1aa56da3</originalsourceid><addsrcrecordid>eNptk99u0zAUxgMCsTF4AG6QJSQ0LtL5T50_0m5C1K2TJjptIC6mKXKd09ZTYgfbGSpvwIPwYjwJDh2FoSoXiXN-3_mOTvJF0SuCRzzj2ZGwnRhRTEmMCefxrHgc7RM-ZjElCX8S7WOMWZznGd-Lnjt3G445peRZtMfGnOdZyvcflWWjtJKiQULX6EL4lWnMUkl0AsL3FhwqnDNSCQ81-qz8Cp3pO-HUHaD3FoTzqBRWKm1asSlTTDJUtGBDU42ughT8GpkF2hrNtBw81kelaRpYwlDcCrYTOO-CFbpSvkfT9dyqWn0TXhmNTq3pO0TRJbi-CdThtG-DctKpGmwbDALwNUxyIqQ3NmASuuGBouvp5JLeHJUra1rjTAuIpKgE7cMZLKDrcnJB0ht0ORihn99_0BH-vZfiDqwIkw56VJpujT707RwsOh6P8LsX0dOFaBy8vL8fRJ9OJh_LaXw-Oz0ri_NYcpz5eFwnuIZEYJZmQFnGQMznPElqnKcsC3tjLIEFlrIW-ZiEep1RylKYEyF4Ugt2EB1u-nbWfOnB-apVTkLTCA2mdxXlaZJwyhgN6Jv_0FvTWx2mq2iSsoTmyTj5Sy1FA5XSC-OtkEPTqkgxzxkJ_06g4h3UEnTYSWM0LFR4_YAf7eDDVUOr5E7B238EKxCNXznT9MPXdg9BsgGlNc5ZWFSdVa2w64rgakhENSSiGhJRDYmoZkXQvL7fRD9vod4q_kSA_QK6hwZG</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2673629646</pqid></control><display><type>article</type><title>Clinical and Pathologic Features Associated With Invasive Breast Carcinoma With 2018 American Society of Clinical Oncology/College of American Pathologists In Situ Hybridization Group 2 Results (Human Epidermal Growth Factor Receptor 2 [HER2]/Chromosome 17 Centromere [CEP17] Ratio ≥2.0 and Average HER2 Copy Number <4.0)</title><source>Allen Press Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Hoda, Raza S ; Zarei, Shabnam ; McIntire, Patrick J ; Sprague, Cathy ; Mekhail, Yasmin ; Carlson, Diane L ; Komforti, Miglena K ; Downs-Kelly, Erinn P</creator><creatorcontrib>Hoda, Raza S ; Zarei, Shabnam ; McIntire, Patrick J ; Sprague, Cathy ; Mekhail, Yasmin ; Carlson, Diane L ; Komforti, Miglena K ; Downs-Kelly, Erinn P</creatorcontrib><description>The American Society of Clinical Oncology/College of American Pathologists updated the human epidermal growth factor receptor 2 (HER2) breast carcinoma testing guideline in 2018 to address issues from uncommon HER2 fluorescence in situ hybridization (FISH) results. Based on the 2013 American Society of Clinical Oncology/College of American Pathologists guideline, cases wherein the HER2/chromosome 17 centromere (CEP17) ratio of 2.0 or more with an average HER2 copy number of less than 4.0 were considered in situ hybridization (ISH) positive. Under the 2018 guideline, such cases are classified as ISH Group 2 and are no longer considered eligible for anti-HER2 therapy when the corresponding HER2 immunohistochemistry result is 0, 1+, or 2+.
To assess the clinical, pathologic, and treatment aspects of patients with ISH Group 2 results.
We retrospectively reviewed HER2 FISH results at our center between January 2012 and December 2014 and identified and characterized cases with ISH Group 2 results.
Thirty-nine cases with ISH Group 2 results from 39 patients were reviewed. Twenty of 39 (51%) patients received anti-HER2 therapy. Patients treated with HER2-targeted therapy were less likely to have hormone receptor-positive tumors, compared with patients without anti-HER2 treatment, though not significantly (P = .30). The only significant difference between the 2 patient groups was receipt of cytotoxic chemotherapy treatment (P < .001). Overall, clinical outcome was similar between the 2 groups (P > .99).
This retrospective study with median follow-up of at least 6 years shows patients with ISH Group 2 tumors had similar clinical outcomes, irrespective of HER2-targeted therapy. Further analysis in the prospective setting would provide valuable data that would potentially inform clinical decision making.</description><identifier>ISSN: 0003-9985</identifier><identifier>ISSN: 1543-2165</identifier><identifier>EISSN: 1543-2165</identifier><identifier>DOI: 10.5858/arpa.2021-0155-OA</identifier><identifier>PMID: 34559875</identifier><language>eng</language><publisher>United States: College of American Pathologists</publisher><subject>Biopsy ; Breast cancer ; Breast carcinoma ; Cellular biology ; Chromosome 17 ; Chromosomes ; Clinical outcomes ; Copy number ; Cytotoxicity ; Diagnostic immunohistochemistry ; Epidermal growth factor ; ErbB-2 protein ; Estrogens ; Fluorescence in situ hybridization ; Hybridization ; In situ hybridization ; Invasiveness ; Lymph nodes ; Metastasis ; Methods ; Oncology ; Patients ; Practice guidelines (Medicine) ; Progesterone ; Progesterone receptors ; Protein-tyrosine kinase receptors ; Radiation therapy ; Trastuzumab ; Tumors</subject><ispartof>Archives of pathology & laboratory medicine (1976), 2022-06, Vol.146 (6), p.701-709</ispartof><rights>COPYRIGHT 2022 College of American Pathologists</rights><rights>Copyright College of American Pathologists Jun 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c508t-4d60de6a0378e2383eabb566d09738201336ef0ccda941383d82237eb1aa56da3</citedby><cites>FETCH-LOGICAL-c508t-4d60de6a0378e2383eabb566d09738201336ef0ccda941383d82237eb1aa56da3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34559875$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hoda, Raza S</creatorcontrib><creatorcontrib>Zarei, Shabnam</creatorcontrib><creatorcontrib>McIntire, Patrick J</creatorcontrib><creatorcontrib>Sprague, Cathy</creatorcontrib><creatorcontrib>Mekhail, Yasmin</creatorcontrib><creatorcontrib>Carlson, Diane L</creatorcontrib><creatorcontrib>Komforti, Miglena K</creatorcontrib><creatorcontrib>Downs-Kelly, Erinn P</creatorcontrib><title>Clinical and Pathologic Features Associated With Invasive Breast Carcinoma With 2018 American Society of Clinical Oncology/College of American Pathologists In Situ Hybridization Group 2 Results (Human Epidermal Growth Factor Receptor 2 [HER2]/Chromosome 17 Centromere [CEP17] Ratio ≥2.0 and Average HER2 Copy Number <4.0)</title><title>Archives of pathology & laboratory medicine (1976)</title><addtitle>Arch Pathol Lab Med</addtitle><description>The American Society of Clinical Oncology/College of American Pathologists updated the human epidermal growth factor receptor 2 (HER2) breast carcinoma testing guideline in 2018 to address issues from uncommon HER2 fluorescence in situ hybridization (FISH) results. Based on the 2013 American Society of Clinical Oncology/College of American Pathologists guideline, cases wherein the HER2/chromosome 17 centromere (CEP17) ratio of 2.0 or more with an average HER2 copy number of less than 4.0 were considered in situ hybridization (ISH) positive. Under the 2018 guideline, such cases are classified as ISH Group 2 and are no longer considered eligible for anti-HER2 therapy when the corresponding HER2 immunohistochemistry result is 0, 1+, or 2+.
To assess the clinical, pathologic, and treatment aspects of patients with ISH Group 2 results.
We retrospectively reviewed HER2 FISH results at our center between January 2012 and December 2014 and identified and characterized cases with ISH Group 2 results.
Thirty-nine cases with ISH Group 2 results from 39 patients were reviewed. Twenty of 39 (51%) patients received anti-HER2 therapy. Patients treated with HER2-targeted therapy were less likely to have hormone receptor-positive tumors, compared with patients without anti-HER2 treatment, though not significantly (P = .30). The only significant difference between the 2 patient groups was receipt of cytotoxic chemotherapy treatment (P < .001). Overall, clinical outcome was similar between the 2 groups (P > .99).
This retrospective study with median follow-up of at least 6 years shows patients with ISH Group 2 tumors had similar clinical outcomes, irrespective of HER2-targeted therapy. Further analysis in the prospective setting would provide valuable data that would potentially inform clinical decision making.</description><subject>Biopsy</subject><subject>Breast cancer</subject><subject>Breast carcinoma</subject><subject>Cellular biology</subject><subject>Chromosome 17</subject><subject>Chromosomes</subject><subject>Clinical outcomes</subject><subject>Copy number</subject><subject>Cytotoxicity</subject><subject>Diagnostic immunohistochemistry</subject><subject>Epidermal growth factor</subject><subject>ErbB-2 protein</subject><subject>Estrogens</subject><subject>Fluorescence in situ hybridization</subject><subject>Hybridization</subject><subject>In situ hybridization</subject><subject>Invasiveness</subject><subject>Lymph nodes</subject><subject>Metastasis</subject><subject>Methods</subject><subject>Oncology</subject><subject>Patients</subject><subject>Practice guidelines (Medicine)</subject><subject>Progesterone</subject><subject>Progesterone receptors</subject><subject>Protein-tyrosine kinase receptors</subject><subject>Radiation therapy</subject><subject>Trastuzumab</subject><subject>Tumors</subject><issn>0003-9985</issn><issn>1543-2165</issn><issn>1543-2165</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNptk99u0zAUxgMCsTF4AG6QJSQ0LtL5T50_0m5C1K2TJjptIC6mKXKd09ZTYgfbGSpvwIPwYjwJDh2FoSoXiXN-3_mOTvJF0SuCRzzj2ZGwnRhRTEmMCefxrHgc7RM-ZjElCX8S7WOMWZznGd-Lnjt3G445peRZtMfGnOdZyvcflWWjtJKiQULX6EL4lWnMUkl0AsL3FhwqnDNSCQ81-qz8Cp3pO-HUHaD3FoTzqBRWKm1asSlTTDJUtGBDU42ughT8GpkF2hrNtBw81kelaRpYwlDcCrYTOO-CFbpSvkfT9dyqWn0TXhmNTq3pO0TRJbi-CdThtG-DctKpGmwbDALwNUxyIqQ3NmASuuGBouvp5JLeHJUra1rjTAuIpKgE7cMZLKDrcnJB0ht0ORihn99_0BH-vZfiDqwIkw56VJpujT707RwsOh6P8LsX0dOFaBy8vL8fRJ9OJh_LaXw-Oz0ri_NYcpz5eFwnuIZEYJZmQFnGQMznPElqnKcsC3tjLIEFlrIW-ZiEep1RylKYEyF4Ugt2EB1u-nbWfOnB-apVTkLTCA2mdxXlaZJwyhgN6Jv_0FvTWx2mq2iSsoTmyTj5Sy1FA5XSC-OtkEPTqkgxzxkJ_06g4h3UEnTYSWM0LFR4_YAf7eDDVUOr5E7B238EKxCNXznT9MPXdg9BsgGlNc5ZWFSdVa2w64rgakhENSSiGhJRDYmoZkXQvL7fRD9vod4q_kSA_QK6hwZG</recordid><startdate>20220601</startdate><enddate>20220601</enddate><creator>Hoda, Raza S</creator><creator>Zarei, Shabnam</creator><creator>McIntire, Patrick J</creator><creator>Sprague, Cathy</creator><creator>Mekhail, Yasmin</creator><creator>Carlson, Diane L</creator><creator>Komforti, Miglena K</creator><creator>Downs-Kelly, Erinn P</creator><general>College of American Pathologists</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>4T-</scope><scope>4U-</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20220601</creationdate><title>Clinical and Pathologic Features Associated With Invasive Breast Carcinoma With 2018 American Society of Clinical Oncology/College of American Pathologists In Situ Hybridization Group 2 Results (Human Epidermal Growth Factor Receptor 2 [HER2]/Chromosome 17 Centromere [CEP17] Ratio ≥2.0 and Average HER2 Copy Number <4.0)</title><author>Hoda, Raza S ; Zarei, Shabnam ; McIntire, Patrick J ; Sprague, Cathy ; Mekhail, Yasmin ; Carlson, Diane L ; Komforti, Miglena K ; Downs-Kelly, Erinn P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c508t-4d60de6a0378e2383eabb566d09738201336ef0ccda941383d82237eb1aa56da3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Biopsy</topic><topic>Breast cancer</topic><topic>Breast carcinoma</topic><topic>Cellular biology</topic><topic>Chromosome 17</topic><topic>Chromosomes</topic><topic>Clinical outcomes</topic><topic>Copy number</topic><topic>Cytotoxicity</topic><topic>Diagnostic immunohistochemistry</topic><topic>Epidermal growth factor</topic><topic>ErbB-2 protein</topic><topic>Estrogens</topic><topic>Fluorescence in situ hybridization</topic><topic>Hybridization</topic><topic>In situ hybridization</topic><topic>Invasiveness</topic><topic>Lymph nodes</topic><topic>Metastasis</topic><topic>Methods</topic><topic>Oncology</topic><topic>Patients</topic><topic>Practice guidelines (Medicine)</topic><topic>Progesterone</topic><topic>Progesterone receptors</topic><topic>Protein-tyrosine kinase receptors</topic><topic>Radiation therapy</topic><topic>Trastuzumab</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hoda, Raza S</creatorcontrib><creatorcontrib>Zarei, Shabnam</creatorcontrib><creatorcontrib>McIntire, Patrick J</creatorcontrib><creatorcontrib>Sprague, Cathy</creatorcontrib><creatorcontrib>Mekhail, Yasmin</creatorcontrib><creatorcontrib>Carlson, Diane L</creatorcontrib><creatorcontrib>Komforti, Miglena K</creatorcontrib><creatorcontrib>Downs-Kelly, Erinn P</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Docstoc</collection><collection>University Readers</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Archives of pathology & laboratory medicine (1976)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hoda, Raza S</au><au>Zarei, Shabnam</au><au>McIntire, Patrick J</au><au>Sprague, Cathy</au><au>Mekhail, Yasmin</au><au>Carlson, Diane L</au><au>Komforti, Miglena K</au><au>Downs-Kelly, Erinn P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical and Pathologic Features Associated With Invasive Breast Carcinoma With 2018 American Society of Clinical Oncology/College of American Pathologists In Situ Hybridization Group 2 Results (Human Epidermal Growth Factor Receptor 2 [HER2]/Chromosome 17 Centromere [CEP17] Ratio ≥2.0 and Average HER2 Copy Number <4.0)</atitle><jtitle>Archives of pathology & laboratory medicine (1976)</jtitle><addtitle>Arch Pathol Lab Med</addtitle><date>2022-06-01</date><risdate>2022</risdate><volume>146</volume><issue>6</issue><spage>701</spage><epage>709</epage><pages>701-709</pages><issn>0003-9985</issn><issn>1543-2165</issn><eissn>1543-2165</eissn><abstract>The American Society of Clinical Oncology/College of American Pathologists updated the human epidermal growth factor receptor 2 (HER2) breast carcinoma testing guideline in 2018 to address issues from uncommon HER2 fluorescence in situ hybridization (FISH) results. Based on the 2013 American Society of Clinical Oncology/College of American Pathologists guideline, cases wherein the HER2/chromosome 17 centromere (CEP17) ratio of 2.0 or more with an average HER2 copy number of less than 4.0 were considered in situ hybridization (ISH) positive. Under the 2018 guideline, such cases are classified as ISH Group 2 and are no longer considered eligible for anti-HER2 therapy when the corresponding HER2 immunohistochemistry result is 0, 1+, or 2+.
To assess the clinical, pathologic, and treatment aspects of patients with ISH Group 2 results.
We retrospectively reviewed HER2 FISH results at our center between January 2012 and December 2014 and identified and characterized cases with ISH Group 2 results.
Thirty-nine cases with ISH Group 2 results from 39 patients were reviewed. Twenty of 39 (51%) patients received anti-HER2 therapy. Patients treated with HER2-targeted therapy were less likely to have hormone receptor-positive tumors, compared with patients without anti-HER2 treatment, though not significantly (P = .30). The only significant difference between the 2 patient groups was receipt of cytotoxic chemotherapy treatment (P < .001). Overall, clinical outcome was similar between the 2 groups (P > .99).
This retrospective study with median follow-up of at least 6 years shows patients with ISH Group 2 tumors had similar clinical outcomes, irrespective of HER2-targeted therapy. Further analysis in the prospective setting would provide valuable data that would potentially inform clinical decision making.</abstract><cop>United States</cop><pub>College of American Pathologists</pub><pmid>34559875</pmid><doi>10.5858/arpa.2021-0155-OA</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0003-9985 |
| ispartof | Archives of pathology & laboratory medicine (1976), 2022-06, Vol.146 (6), p.701-709 |
| issn | 0003-9985 1543-2165 1543-2165 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2576652332 |
| source | Allen Press Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Biopsy Breast cancer Breast carcinoma Cellular biology Chromosome 17 Chromosomes Clinical outcomes Copy number Cytotoxicity Diagnostic immunohistochemistry Epidermal growth factor ErbB-2 protein Estrogens Fluorescence in situ hybridization Hybridization In situ hybridization Invasiveness Lymph nodes Metastasis Methods Oncology Patients Practice guidelines (Medicine) Progesterone Progesterone receptors Protein-tyrosine kinase receptors Radiation therapy Trastuzumab Tumors |
| title | Clinical and Pathologic Features Associated With Invasive Breast Carcinoma With 2018 American Society of Clinical Oncology/College of American Pathologists In Situ Hybridization Group 2 Results (Human Epidermal Growth Factor Receptor 2 [HER2]/Chromosome 17 Centromere [CEP17] Ratio ≥2.0 and Average HER2 Copy Number <4.0) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T13%3A44%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20and%20Pathologic%20Features%20Associated%20With%20Invasive%20Breast%20Carcinoma%20With%202018%20American%20Society%20of%20Clinical%20Oncology/College%20of%20American%20Pathologists%20In%20Situ%20Hybridization%20Group%202%20Results%20(Human%20Epidermal%20Growth%20Factor%20Receptor%202%20%5BHER2%5D/Chromosome%2017%20Centromere%20%5BCEP17%5D%20Ratio%20%E2%89%A52.0%20and%20Average%20HER2%20Copy%20Number%20%3C4.0)&rft.jtitle=Archives%20of%20pathology%20&%20laboratory%20medicine%20(1976)&rft.au=Hoda,%20Raza%20S&rft.date=2022-06-01&rft.volume=146&rft.issue=6&rft.spage=701&rft.epage=709&rft.pages=701-709&rft.issn=0003-9985&rft.eissn=1543-2165&rft_id=info:doi/10.5858/arpa.2021-0155-OA&rft_dat=%3Cgale_proqu%3EA705931985%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2673629646&rft_id=info:pmid/34559875&rft_galeid=A705931985&rfr_iscdi=true |